

2022 Virtual MS Summit
May 21, 2022

DISCLOSURE INFORMATION

The University of Washington School of Medicine requires any person in control of content disclose any financial relationships with ineligible companies whose products or services are discussed in educational presentations. Significant relationships include receiving from an ineligible company research grants, consultancies, honoraria and travel, or other benefits or having a self-managed equity interest in a company. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. The ACCME defines an ineligible entity as a company" whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients."

The University of Washington School of Medicine, as part of its accreditation from the Accreditation Council on Continuing Medical Education (ACCME), is required to "mitigate" any conflicts prior to the educational program. Therefore, in light of the relationships/affiliations designated, each person in control of content has attested that:

- recommendations for patient care are based on current science, evidence, and clinical reasoning, while giving a fair and balanced view of diagnostic and therapeutic options;
- all scientific research referred to, reported, or used in this educational activity in support or justification of a patient care recommendation conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation;
- new and evolving topics for which there is a lower (or absent) evidence base are clearly identified as such;
- content avoids advocating for, or promoting, practices that are not, or not yet, adequately based on current science, evidence, and clinical reasoning;
- content excludes any advocacy for, or promotion of, unscientific approaches to diagnosis or therapy, or recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.

The following have disclosed the described relationships:

Role **Description of Relationship**

Planner: Annette Wundes, MD- Research funding with Biogen, Alkermes, AbbVie (Relationships with Biogen and Alkermes have ended)

Planner/Speaker: Nina Bozinov, MD- Emerging Leaders Roundtable with Novartis. Advisory Board with Biogen. (Relationships have ended)

Planner/Speaker: Angeli Mayadev, MD- Consultant/Advisory/Research for AbbVie. Consultant/Advisory for Ipsen

Planner: Stacy Donlon, MD- Consulting/Speaking with Biogen, EMD Serono, Genentech, Genzyme, Bristol Myers

Planner: Kathryn Fong, MD- CME Case Writer with Point of Care (formerly Projects in Knowledge). Consultant with EMD Serono.

Speaker: *Darin Okuda, MD, FAAN, FANA - Consultant/Advisory with Biogen, Celgene, Bristol Myers Squibb, EMD Serono, Genentech, Genzyme, Janssen Pharmaceuticals, Novartis, Osmotica Pharmaceuticals, RVL Pharmaceuticals, Inc., TG Therapeutics, Viela Bio, Inc. Research support from Biogen and EMD Serono/Jvlerck. Royalties for intellectual property licensed by The Board of Regents of The University of Texas System.*

Speaker: *Jennifer Graves, MD, PhD – Advisory with Genentech and Bayer*

The following have indicated they do not have any relationships to disclose:

Planner: *Lucas McCarthy, MD*

Planner/Speaker: *Gloria von Geldern, MD*

Planner: *Jodie Haselkorn, MD*

All relevant financial relationships listed have been mitigated.